Anheuser-Busch InBev 2023 Projection: Even though conservatives were unhappy with Bud Light’s transgender marketing campaign, Anheuser-Busch InBev (ABI.BR) maintained their 2023 projection. Anheuser-Busch InBev maintained its 2023 projection despite these issues. After the COVID-19 pandemic, the company rebounded in China.
The world’s largest brewery’s stock opened up 2.6%. One of the best-performing stocks in the FTSEurofirst 300 index (.FTEU3), including Europe’s top stocks, was 52.40 euros. A.B. InBev, which sells 25% of the world’s beer, lost 1.4% in the second quarter. Because costs changed and clients bought more expensive things, prices grew 9.0% yearly.
EBITDA rose 5.0% from April to June. $4.91 billion. This performance exceeded the company’s 0.4% prediction. Heineken (HEIN.AS), the world’s second-largest brewer, needed better results and cut its 2023 estimate due to Vietnam’s slowing growth and price increases that affected volume. SABMiller, the world’s largest brewery, did well.
A.B. InBev’s China sales increased significantly. Sales of premium beers increased by almost 20%, while volume sales rose 11%. The outbreak increased revenue and profit. Sales and profit margins improved in critical nations like Brazil and Mexico. Europe and Colombia saw similar positive effects.
A.B. InBev’s biggest market, the U.S., was different. Constellation Brands’ (STZ.N) Modelo Especial overtook Bud Light, the company’s most popular brand. People disliked a social media promotion featuring transgender influencer Dylan Mulvaney. Bud Light shop sales have decreased by 25% since April. Recent consumer research found that 80% of respondents had positive or neutral feelings about the brand, suggesting sales have decreased.
Coors Light and Miller Lite, brewed by Molson Coors (TAP.N), Bud Light’s primary U.S. competitor, did well, while Bud Light did not. After its finest quarter since merging with Coors in 2005, Molson Coors raised its outlook.
A.B. InBev is optimistic about 2023 despite U.S. issues. The company maintains its medium-term EBITDA growth target of 4% to 8%. Revenue increase exceeds EBITDA growth.